Physician profile
Arvind Kumar Salwan
NPI 1437230190
$5,681.35
in general payments reported to CMS, 2019-2025
40 companies · $514 in 2025
The $514 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,030 · 2020: $820 · 2021: $1,068 · 2022: $1,078 · 2023: $723 · 2024: $448 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,645 · Education: $39.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,644.84 |
| Education | $39.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $778.49 | 2020-2024 | Ubrelvy, Qulipta, Linzess |
| Bayer Healthcare Pharmaceuticals INC. | $592.12 | 2021-2025 | |
| Allergan, INC. | $480.15 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $323.74 | 2019-2025 | Verquvo, Belsomra, Winrevair |
| Esperion Therapeutics, INC. | $283.67 | 2020-2024 | Nexletol |
| Radius Health, INC. | $257.31 | 2019-2021 | |
| Pfizer INC. | $244.23 | 2019-2025 | |
| Corcept Therapeutics | $237.88 | 2023-2025 | Korlym |
| Lilly USA, LLC | $233.55 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Sunovion Pharmaceuticals INC. | $210.06 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $203.25 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.59 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $183.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Philips North America LLC | $179.41 | 2019-2025 | Encore, (8874) Incourage |
| Novartis Pharmaceuticals Corporation | $138.53 | 2019-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Salwan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.